Antiinflammatory Therapy with Canakinumab for Atherosclerotic DiseasePaul M. Ridker, Robert J. Glynn, Daniel Pella et al.|New England Journal of Medicine|2017Cited by 9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trialPaul M. Ridker, Hakan Kültürsay, Jean MacFadyen et al.|The Lancet|2017Cited by 1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trialPaul M. Ridker, Patrick Commerford, Jean MacFadyen et al.|The Lancet|2017Cited by 881
The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular diseaseJoAnn E. Manson, Julie E. Buring, Shari S. Bassuk et al.|Contemporary Clinical Trials|2011Cited by 553
Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial.Christine M. Albert, JoAnn E. Manson, Nancy R. Cook et al.|PubMed|2008Cited by 512